Dexmedetomidine alleviates CoCl2-induced hypoxic cellular damage in INS-1 cells by regulating autophagy
Korean Journal of Anesthesiology · 01.12.2024 · 77 (6) · 623-634
DOI: 10.4097/kja.24457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Anesthesiology, erschienen am 01.12.2024. Verfasst von Jin Ha Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Dexmedetomidine, Autophagy, Cobalt. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korean Society of Anesthesiologists.
Abstract (Originalsprache)
Background
Ischemia-reperfusion (I/R) injury is inevitable during the perioperative period. The pancreas is susceptible to I/R injury. Autophagy, a self-digestion process, is upregulated during I/R injury and strongly induced by hypoxia. This study aims to determine whether dexmedetomidine can decrease pancreatic β-cell damage by regulating autophagy under hypoxia.
Methods
INS-1 rat insulinoma cells were cultured in dexmedetomidine before being exposed to cobalt chloride (CoCl2)-induced hypoxia. Cell viability and the expression of autophagy-related proteins (light chain 3B [LC3B]-II, p62, and ATGs) were assessed. The expression of apoptosis-related proteins (BCL-2 and P-BAD) were also evaluated. CoCl2-treated INS-1 cells were pretreated with the autophagosome formation inhibitor, 3-methyladenine (3-MA), to compare its effects with those of dexmedetomidine. Bafilomycin-A1 (Baf-A1) that inhibits autophagosome degradation was used to confirm the changes in autophagosome formation induced by dexmedetomidine.
Results
Dexmedetomidine attenuated the increased expression of autophagic proteins (LC3B-II, p62, and ATGs) and reversed the CoCl2-induced reduction in the proliferation of INS-1 cells after hypoxia. Dexmedetomidine also alleviated the decreased expression of the anti-apoptotic protein (BCL-2) and the increased expression of apoptotic protein (BAX). Dexmedetomidine reduces the activation of autophagy through inhibiting autophagosome formation, as confirmed by a decrease in LC3B-II/I ratio, a marker of autophagosome formation, in LC3B turnover assay combined with Baf-A1.
Conclusions
Dexmedetomidine alleviates the degree of cellular damage in INS-1 cells against CoCl2-induced hypoxia by regulating autophagosome formation. These results provide a basis for further studies to confirm these effects in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Förderung
- Korean Society of Anesthesiologists
Zitieren
APA
Park, J. H., Oh, J. E., Kim, N., & Kwak, Y. L. (2024). Dexmedetomidine alleviates CoCl2-induced hypoxic cellular damage in INS-1 cells by regulating autophagy. Korean Journal of Anesthesiology, 77(6), 623-634. https://doi.org/10.4097/kja.24457
Vancouver
Park JH, Oh JE, Kim N, Kwak YL. Dexmedetomidine alleviates CoCl2-induced hypoxic cellular damage in INS-1 cells by regulating autophagy. Korean Journal of Anesthesiology. 2024;77(6):623-634. doi:10.4097/kja.24457
BibTeX
@article{Park2024,
author = {Park, Jin Ha and Oh, Ju Eun and Kim, Namo and Kwak, Young-Lan},
title = {Dexmedetomidine alleviates CoCl2-induced hypoxic cellular damage in INS-1 cells by regulating autophagy},
journal = {Korean Journal of Anesthesiology},
year = {2024},
volume = {77},
number = {6},
pages = {623--634},
doi = {10.4097/kja.24457}
}
EUVIMED